|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-10-15
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Maraviroc treatment for HIV-1 infected patients results in larger CD4(+) T cell rises than are attributable to its antiviral activity alone. We investigated whether this is due to modulation of T cell activation and inflammation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1932-6203
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e13188
|
|
pubmed:meshHeading |
pubmed-meshheading:20949133-Benzoxazines,
pubmed-meshheading:20949133-CD4 Lymphocyte Count,
pubmed-meshheading:20949133-Case-Control Studies,
pubmed-meshheading:20949133-Cyclohexanes,
pubmed-meshheading:20949133-HIV Fusion Inhibitors,
pubmed-meshheading:20949133-HIV Infections,
pubmed-meshheading:20949133-Humans,
pubmed-meshheading:20949133-Receptors, CCR5,
pubmed-meshheading:20949133-Reverse Transcriptase Inhibitors,
pubmed-meshheading:20949133-Triazoles,
pubmed-meshheading:20949133-Viral Load
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.
|
|
pubmed:affiliation |
Case Western Reserve University, Cleveland, Ohio, United States of America.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
